Proportion of single-chain recombinant tissue plasminogen activator and outcome after stroke.

Fiche publication


Date publication

décembre 2016

Journal

Neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MOULIN Thierry


Tous les auteurs :
Leys D, Hommet Y, Jacquet C, Moulin S, Sibon I, Mas JL, Moulin T, Giroud M, Sagnier S, Cordonnier C, Medeiros de Bustos E, Turc G, Ronzière T, Bejot Y, Detante O, Ouk T, Mendyk AM, Favrole P, Zuber M, Triquenot-Bagan A, Ozkul-Wermester O, Montoro FM, Lamy C, Faivre A, Lebouvier L, Potey C, Poli M, Hénon H, Renou P, Dequatre-Ponchelle N, Bodenant M, Debruxelles S, Rossi C, Bordet R, Vivien D,

Résumé

To determine whether the ratio single chain (sc)/(sc + 2 chain [tc]) recombinant tissue plasminogen activator (rtPA) influences outcomes in patients with cerebral ischemia.

Mots clés

Aged, Aged, 80 and over, Brain Ischemia, complications, Cerebral Hemorrhage, complications, Disability Evaluation, Female, Fibrinolytic Agents, chemistry, Humans, Male, Middle Aged, Recombinant Proteins, chemistry, Seizures, complications, Severity of Illness Index, Stroke, complications, Thrombolytic Therapy, Time-to-Treatment, Tissue Plasminogen Activator, chemistry, Treatment Outcome

Référence

Neurology. 2016 Dec 6;87(23):2416-2426